IonQ stock rose 2.0% following several announcements. The company was awarded a contract under the Missile Defense Agency's SHIELD indefinite-delivery/indefinite-quantity contract with a ceiling value of $151 billion, allowing IonQ to compete for future task orders. Additionally, IonQ announced third quarter 2025 financial results showing revenue of $39.9 million, exceeding the high end of guidance by 37% and representing 222% year-over-year growth. The company completed acquisitions of Oxford Ionics and Vector Atomic, achieved a world-record 99.99% two-qubit gate performance, and reached its #AQ 64 technical milestone three months ahead of schedule. IonQ also secured a new contract with Oak Ridge National Laboratory and raised $2 billion through an equity offering, bringing pro-forma cash and investments to $3.5 billion as of September 30, 2025.
Read full analysisIonQ stock rose 2.0% following several announcements. The company was awarded a contract under the Missile Defense Agency's SHIELD indefinite-delivery/indefinite-quantity contract with a ceiling value of $151 billion, allowing IonQ to compete for future task orders. Additionally, IonQ announced third quarter 2025 financial results showing revenue of $39.9 million, exceeding the high end of guidance by 37% and representing 222% year-over-year growth. The company completed acquisitions of Oxford Ionics and Vector Atomic, achieved a world-record 99.99% two-qubit gate performance, and reached its #AQ 64 technical milestone three months ahead of schedule. IonQ also secured a new contract with Oak Ridge National Laboratory and raised $2 billion through an equity offering, bringing pro-forma cash and investments to $3.5 billion as of September 30, 2025.
IonQ builds trapped-ion quantum computers and sells access via major cloud platforms including Amazon Web Services and Microsoft Azure. The stock has lost roughly 30% since late January following a $1.8 billion SkyWater Technology acquisition, a Wolfpack Research short report questioning its revenue practices, and a subsequent securities fraud investigation. With Q4 earnings due February 25 and a new MDA defense contract partially countering the short-seller narrative, the stock sits at a critical inflection point between bearish overhang and potential fundamental validation.